How to Buy Tarsus Pharmaceuticals Stock
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions.
Tarsus Pharmaceuticals stock last closed at $74.85, up 0.88% from the previous day, and has increased 8.54% in one year. It has overperformed other stocks in the Biotechnology industry by 0.75 percentage points. Tarsus Pharmaceuticals stock is currently +38.89% from its 52-week low of $53.89, and -18.22% from its 52-week high of $91.53.
At the moment, there are 43.88M TARS shares outstanding. The market value of TARS is $3.28B. In the last 24 hours, 586,000 TARS shares were traded.
How to Buy Tarsus Pharmaceuticals Stock
Wondering how to invest in Tarsus Pharmaceuticals stock? Here's how.
- Choose where to buy Tarsus Pharmaceuticals stock: You need to choose a stock brokerage, but don't worry - we've researched dozens of online stock brokerages and apps to help you choose where to buy Tarsus Pharmaceuticals stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Choose your payment method and add your information.
- Research Tarsus Pharmaceuticals stock: The Tarsus Pharmaceuticals ticker symbol is TARS. Is Tarsus Pharmaceuticals stock a good investment? Should you buy shares of TARS? How do TARS's underlying business fundamentals look? Do top analysts think Tarsus Pharmaceuticals is a good buy? Why has TARS's stock price moved recently? (Hint: Our stock market analysis tools can help you decide if TARS is a good stock to buy).
- Make your TARS buy order: Decide if you will purchase TARS shares at the current market price or use a limit order to purchase TARS stock at a particular price.
- Keep tabs on your TARS investment: Create a watchlist to key updates about your new investment in Tarsus Pharmaceuticals shares.
Step 1: Choose where to buy Tarsus Pharmaceuticals stock
You need a brokerage account in order to access the NASDAQ market and buy TARS shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Technology to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro has a community of more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've selected your brokerage, the next step is to fill out some personal info so you are able to buy TARS stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to create a new brokerage account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have finished signing up on the best stock investing app, your next step is to transfer the money for your investment:
Check out the video below to see the process of depositing money into your new investment account.
Step 4: Research Tarsus Pharmaceuticals stock
After you have figured out the best place to buy Tarsus Pharmaceuticals stock, it's very important to analyze their stock before you buy, so you truly wrap your head around the risk as well as the opportunity.
Tarsus Pharmaceuticals shares quick numbers
TARS Fundamentals
WallStreetZen was built to help average investors perform more accurate fundamental analysis in less time.
You can view all of the due diligence checks on TARS's stock page.
Is TARS stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge TARS's true value.
Using relative valuations measures:
- TARS may be overvalued based on its P/B ratio of 9.47x, relative to Biotechnology industry P/B ratio of 5.2x
You can access more valuation analysis on TARS's stock here.
TARS Financial Overview
Pros:
- There are more short-term assets than long-term liabilities on the TARS balance sheet.
- TARS profit margin has gone up from -31.1% to -7.7% in the past year.
- TARS's operating cash flow of $74.16M allows it to safely service it's debt of $72.76M.
- There are more short-term assets than short-term liabilities on the TARS balance sheet.
Cons:
- TARS has a relatively high debt to equity ratio of 0.76.
- TARS earnings of -$30.58M is not sufficient to cover its interest payments.
- Total TARS debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Tarsus Pharmaceuticals stock, according to Wall Street analysts?
Out of 7 Wall Street analysts who track TARS, the consensus analyst rating on TARS is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Most Recent TARS Analyst Ratings
Bradley Canino, a top 18% analyst from Guggenheim maintains TARS with a strong buy rating and lowers their TARS price target from $90.00 to $89.00, on Jul 21, 2026.
Matthew Caufield, a top 12% analyst from HC Wainwright & Co. reiterates TARS with a buy rating and maintains their TARS price target from $88.00 to $88.00, on Jul 9, 2026.
You can dig deeper into what analysts are projecting on the Tarsus Pharmaceuticals stock forecast page.
TARS Technical Indicators
Is TARS Making Money?
Last year, TARS revenue was $606.33M. In the past 5 year, TARS's revenue has gone up by 61.35% per year. This was faster than the Biotechnology industry average of 30.13%.
Learn more about TARS's earnings and revenue performance here.
What are TARS executives and large shareholders up to?
Over the past year, executives and large shareholders at TARS have sold more shares than they have bought.
William J. Phd Link, Director of TARS, was the latest TARS insider to sell. They sold $914,502.75 worth of TARS stock on Sep 15, 2026.
Research more about who owns TARS stock here.
Does TARS stock generate passive income?
No, Tarsus Pharmaceuticals doesn't provide an income stream by paying out dividends.
What others are saying about TARS
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Make your TARS buy order
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a given price, place a limit order.
Press the Open Trade button and eToro will execute the order.
If you need more info about buying stocks on eToro, watch the how to video below:
Step 6: Keep tabs on your TARS investment
Now that you own some shares in TARS, you'll want to keep up with your new investment.
Make a watchlist to get notified of the latest news about your TARS stock.
TARS Feed
How to Buy Stock in Tarsus Pharmaceuticals
To reiterate, here are the 6 steps you need to take to buy Tarsus Pharmaceuticals stock right now:
- Choose where to buy Tarsus Pharmaceuticals stock
- Create a brokerage account
- Fund your brokerage account
- Research Tarsus Pharmaceuticals stock
- Make your TARS buy order
- Keep tabs on your TARS investment
If you require a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Tarsus Pharmaceuticals, create a watchlist today.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.